Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

Calgary, Alberta (ots/PRNewswire) -

The commencement of this Phase 1 pharmacokinentic (PK) trial in
patients with severe renal impairment is the first in a series of
planned clinical trials designed with value creation in mind.

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today
announced that dosing has commenced in a Phase 1 PK study with lead
drug candidate apabetalone (RVX-208) in patients with severe renal
impairment.

While the Company's Phase 3 BETonMACE trial, designed for
high-risk cardiovascular disease patients with type 2 diabetes and
low HDL is enrolling as planned, this Phase 1 trial has been
initiated and designed in accordance with the Company's strategy to
expand into new indications such as renal (chronic kidney disease)
and orphan diseases with our lead candidate, apabetalone. This trial
has the potential to create increased value for apabetalone in new
high-risk patient segments which have shorter development paths to
product registration and market adoption.

The primary objective of the Phase 1 study, based in New Zealand,
is to determine if apabetalone treated patients with severe renal
impairment have the same favorable PK traits as has been witnessed in
previous apabetalone trials. Results are expected in the second half
of 2016, and if successful, will allow for more advanced renal
impairment and dialysis trials to proceed. The study will also
explore acute changes in biomarkers relevant to Bromodomain and
Extra-Terminal (BET) inhibition in subjects with severe renal
impairment. Two cohorts, each comprised of eight subjects, will be
evaluated in the study. Cohort one will include subjects with
end-stage renal disease (ESRD) not on dialysis, with an estimated
glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m[2]
while cohort two will include healthy individuals whose age, weight
and gender will be matched to the renal impaired subjects. All
subjects will receive a single oral administration of 100mg of
apabetalone.

Dr. Kamyar Kalantar-Zadeh, Chairman of the Renal Clinical Advisory
Board, and member of the BETonMACE Clinical Steering Committee
stated, "The results from this study will further assist the Company
in advancing planned Phase 2 trials into expanded renal indications.
Additionally, potential effects on novel biomarkers and pathways
affected by select BET inhibition in patients with severe renal
impairment may be elucidated and provide insight for the
pre-specified subgroup in Resverlogix's Phase 3 clinical trial
BETonMACE, where is it anticipated that approximately 15 percent of
subjects will have moderate renal impairment."

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class,
small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set of
biological effects with potentially important benefits for patients
with diseases such as high-risk cardiovascular disease (CVD),
diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease,
Orphan diseases, and peripheral artery disease, while maintaining a
well described safety profile. Apabetalone is the only selective BET
bromodomain inhibitor in human clinical trials, currently in a Phase
3 trial BETonMACE in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).

For further information please visit http://www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX
(https://twitter.com/resverlogix_rvx)
(https://twitter.com/resverlogix_rvx), or on our blog at
http://www.resverlogix.com/blog

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to the Company's Phase 3
clinical trial and the potential role of apabetalone in the treatment
of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan
diseases, and peripheral artery disease. Our actual results, events
or developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance
that any of the events or expectations will occur or be realized. By
their nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our Annual
Information Form and most recent MD&A which are incorporated herein
by reference and are available through SEDAR at http://www.sedar.com.
The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: +1-403-254-9252